Compare Frontline Plc Ordinary Shares (FRO) vs GE HealthCare Technologies Inc. Common Stock (GEHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Frontline Plc Ordinary Shares vs GE HealthCare Technologies Inc. Common Stock — how do they compare? Frontline Plc Ordinary Shares trades at $54.93 (market cap $13.14B), while GE HealthCare Technologies Inc. Common Stock trades at $68.66 (market cap $31.07B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 2.4× Frontline Plc Ordinary Shares's market cap, and Frontline Plc Ordinary Shares pays the higher dividend (9.11%). Which is the better fit depends on your goals.
| FRO | GEHC | |
|---|---|---|
Market Cap | $13.14B | $31.07B |
Volume | 3,351,547 | 3,443,020 |
Sector | Industrials | Health |
52-Week High | $59.19 | $88.16 |
52-Week Low | $20.58 | $59.48 |
Typical Hold Time | 1 Days | — |
Enterprise Value | $15.26B | $39.53B |
Dividend Yield | 9.11% | 0.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Frontline (FRO) trades at $59.04, down 0.25% on the day, but maintains a strong technical and fundamental position. The stock is near its 52-week high, supported by bullish moving averages and robust earnings, with Q2 2026 EPS beating estimates at $2.96. Revenue and profitability have surged, with 2026 net income margin projected at 54.75%. Recent news highlights a special dividend declaration and institutional buying interest.
The outlook for FRO is positive, driven by record earnings and favorable shipping market dynamics. Investment opportunities include strong cash flow generation and shareholder returns, but risks involve exposure to volatile freight rates and geopolitical tensions affecting global trade. Analyst sentiment is mixed, with a 'Hold' consensus suggesting cautious optimism amid near-term highs.
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Frontline Plc Ordinary Shares
Frontline operates a fleet of oil tankers that transport crude oil by sea. Its vessels serve global energy trading routes.
Read more on FRO →About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →
